TrialCardiovascular diabetology2020

Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.

Hassan B Awal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.